Harmony Biosciences Acquires Epygenix Therapeutics

Harmony Biosciences Acquires Zynerba Pharmaceuticals

August 14, 2023

Pharmaceuticals

Harmony Biosciences Holdings, Inc. has signed a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. in a cash tender offer valued at $60 million at closing ($1.1059 per share) plus a non-tradeable contingent value right (CVR) with potential additional payments of up to $140 million, for total potential consideration of up to $200 million. The deal is expected to close in the fourth quarter of 2023, subject to customary closing conditions and tendering by at least a majority of Zynerba’s outstanding shares.

Kyruus Acquires Epion Health

September 13, 2022

Healthcare Services

Kyruus, a provider search and scheduling platform, has acquired Epion Health, a digital patient engagement company based in Hoboken, New Jersey. The deal combines Kyruus's provider search and scheduling capabilities with Epion's pre-visit intake, patient engagement, and payment tools to create an end-to-end patient access and engagement offering for health systems and medical groups.

Biogen Acquires Alcyone Therapeutics

September 19, 2025

Medical Devices

Biogen has acquired Alcyone Therapeutics to obtain the ThecaFlex DRx intrathecal drug‑delivery system, integrating Alcyone employees into Biogen’s product delivery solutions team. Alcyone will receive $85 million upfront plus contingent milestone payments; Biogen will handle development, commercialization and manufacturing of ThecaFlex DRx while Alcyone’s remaining therapeutic assets are being divested into Neela Therapeutics.

Genexine Announces Merger with EPD Biotherapeutics (EPD Bio)

July 4, 2024

Biotechnology

Genexine, a clinical-stage Korean biopharmaceutical company, announced a small-scale merger with EPD Biotherapeutics (EPD Bio) to strengthen its drug development pipeline. The merger is intended to add PROTAC/bioPROTAC (bioPROTAC via EPDegTM mRNA-LNP) technology talent and expand Genexine’s R&D capabilities, with EPD Bio’s founder joining Genexine to lead R&D.

UCB to Acquire Zogenix for up to $1.9B

January 19, 2022

Pharmaceuticals

UCB (Euronext: UCB) has agreed to acquire Zogenix, Inc. (NASDAQ: ZGNX) in a cash tender offer valuing the deal at up to approximately US$1.9 billion, consisting of US$26.00 per share in cash plus a contingent value right of up to US$2.00 per share tied to regulatory milestones. The acquisition adds Zogenix's FINTEPLA (fenfluramine) — an approved treatment for seizures associated with Dravet syndrome and under review for Lennox-Gastaut syndrome — to UCB's neurology and rare disease portfolio and is expected to expand UCB's epilepsy pipeline and global commercial reach.

Astellas Pharma Acquires Xyphos Biosciences

December 26, 2019

Biotechnology

Astellas Pharma has acquired Xyphos Biosciences, gaining Xyphos' ACCEL convertible-CAR technology platform and immuno-oncology talent. The deal included $120 million paid at closing and potential milestone payments bringing the total transaction value to up to $665 million.